In the Media

Viewing records where tag name contains "media" View All

ADCs Built On Starpharma Delivery Tech To Be Tested By Merck

Aug 22nd, 2022

"As it works to expand its antibody-drug conjugate (ADC) capabilities, Merck has strengthened its links to Starpharma by signing a second partnership that will allow it to assess potential candidates using a dendrimer drug delivery technology", reports World Pharma Today.

Read More

Merck bags chance to test ADCs based on Starpharma delivery tech

Aug 16th, 2022

"Merck has tightened its ties to Starpharma as it continues to build out its antibody-drug conjugate (ADC) capabilities, signing a second agreement that will enable it to evaluate candidates based on a dendrimer drug delivery platform", as featured in Fierce Pharma. 

Read More

Starpharma announces new research agreement for DEP drug delivery platform

Aug 11th, 2022

"Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and characterisation," as reported in The National Tribune.

Read More

Starpharma (ASX:SPL) signs new DEP research agreement with MSD

Aug 10th, 2022

Following Starpharma's latest announcement, the company was featured in The Market Herald. 

Read More

Starpharma one of a number of Australian companies in the US for major oncology conference

Jun 7th, 2022

"For the first time in more than two years, a number of Australian biotechnology companies are in the US for one of the world's most important oncology events - the global conference of the American Society of Clinical Oncology (ASCO)." Starpharma featured in Biotech Dispatch during its visit to the United States for ASCO. 

Read More

Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer

Nov 30th, 2021

Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.

Read More

Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer

Nov 27th, 2021

Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha. 

Read More

Starpharma Releases Positive DEPĀ® Phase 2 Interim Results In Prostate Cancer

Nov 27th, 2021

British Herald reports on Starpharma's announcement, regarding the positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.

Read More

Starpharma Announces Encouraging Interim Results for Prostate Cancer Drug

Nov 27th, 2021

Gene Online reports on the news of Starpharma's latest announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel. 

Read More